Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.

Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multicenter, observational study we aimed to assess the safety and efficacy of standard CD19 CAR T in patients 80 years of age or older. At total of 88 patients, median age 82 (range, 80-89) years, were included.

Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy.

Background: Survival in mantle cell lymphoma (MCL) has improved over time, with 1 potential reason being approval of new therapies. We hypothesized that access to multiple new agents with nonoverlapping mechanisms of action would result in significant improvements in overall survival.

Patients And Methods: Patients ages > 65 and diagnosed with MCL between 2002 and 2019 were identified using the SEER-Medicare linked database.